title: [Detection of peripheral blood HBV-LHBs transactivation function and its relationship with anti-viral efficacy].
abstract: OBJECTIVE
  Explore the serum of patients with CHB of HBV large envelope protein (HBV-LHBs) trans-activation function and antiviral therapy effect relationship.
  
  
  METHODS
  60 cases of anti-viral treatment of patients with chronic hepatitis B to take every 3 months HBVDNA, HBV-LHBs, as well as detection of hepatitis B immune markers to observe the changes in indexes.
  
  
  RESULTS
  Income group 60 cases of anti-virus group HBVDNA with HBV-LHBs have a higher detection rate of the consistency of the results found no statistical significance (P > 0.05), HBV-LHBs-positive rate and positive rate of HBeAg differences (chi2 = 4.08, P < 0.05). After 24 months of antiviral therapy HBV-LHBs expression always HBVDNA in 29 cases of which occurred 24 months after the negative reaction of the 20 cases, continuous positive were seven cases of non-negative. 60 cases of patients 24 months found no HBsAg seroconversion, four cases of emergence of HBeAg seroconversion.
  
  
  CONCLUSIONS
  (1) detection of serum HBV-LHBs to reflect the hepatitis B virus replication with HBVDNA good correlation. (2) anti-viral treatment of dynamic observation of the process of HBV-LHBs expression can predict the effectiveness of anti-viral therapy.
authors.affiliation: The laboratory of Hangzhou Sixth People's Hospital, Hangzhou 310014, China.
authors.forename: Ai-fang
authors.initials: AF
authors.lastname: Xu
authors.forename: Gang
authors.initials: G
authors.lastname: Chen
authors.forename: Miao-chan
authors.initials: MC
authors.lastname: Wang
authors.forename: Dong-ming
authors.initials: DM
authors.lastname: Sui
authors.forename: Xiu-ya
authors.initials: XY
authors.lastname: Zhu
authors.forename: Jun-ping
authors.initials: JP
authors.lastname: Shi
authors.forename: Yong-le
authors.initials: YL
authors.lastname: Zhang
authors.forename: Guo-qiang
authors.initials: GQ
authors.lastname: Lou
mesh_terms: D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D004279:DNA, Viral / Q000097:blood* / Q000235:genetics; D005260:Female; D006509:Hepatitis B / Q000097:blood / Q000188:drug therapy* / Q000821:virology; D006511:Hepatitis B Antigens / Q000097:blood / Q000235:genetics; D006515:Hepatitis B virus / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification / Q000502:physiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D014759:Viral Envelope Proteins / Q000097:blood* / Q000235:genetics; D014775:Virus Activation / Q000187:drug effects*; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D006511:Hepatitis B Antigens; C096362:L protein, hepatitis B virus; D014759:Viral Envelope Proteins